Navigation Links
Pharmaceuticals Announces $1.5 Million Second Closing in Private Placement
Date:1/31/2013

VANCOUVER, British Columbia and MENLO PARK, Calif., Jan. 31, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced the second closing in a private placement consisting of approximately 1.9 million units of its securities to qualified accredited investors, for gross proceeds of approximately $1.5 million. The total amount raised in the private placement is $6.9 million.

DelMar announced a first closing of $5.4 million on January 25, 2013.

Charles Vista LLC acted as the company's placement agent in the unit offering. Each unit consists of one share of common stock and one common stock purchase warrant.

Jeffrey Bacha , Chief Executive Officer of DelMar, commented "We are pleased to announce this second closing to raise additional funds and are very encouraged by the overall level of investor interest in our private placement. We continue to enhance our financial position to expand and accelerate our drug development activities with our lead drug candidate, VAL-083." 

About DelMar Pharma
Del Mar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.  VAL-083 benefits from extensive clinical research sponsored by the US National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.

Safe Harbor Statement
Any state
'/>"/>

SOURCE DelMar Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... May 29, 2015  Epic Sciences announced today that ... from metastatic castrate resistant prostate cancer patients, at ... for Clinical Oncology. This application expands the investigational ... behind™ platform to characterize circulating tumor cell ... stage patients have heterogeneous clonal CTC populations harboring ...
(Date:5/29/2015)... 29, 2015 Amgen (NASDAQ: AMGN ... Phase 3, global, randomized, placebo-controlled trials evaluating AMG ... secondary hyperparathyroidism (SHPT) in patients with chronic kidney ... primary endpoint, demonstrating that a greater proportion of ... greater than 30 percent reduction in parathyroid hormone ...
(Date:5/29/2015)... Pa. , May 29, 2015 ... focus of the Association for the Advancement of ... With support from AAWC,s corporate partners, ... Educational Portal on the AAWC website at ... a wound care pathway with links to various ...
Breaking Medicine Technology:Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity 2Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity 3Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 2Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 3Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 4Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 6Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 7The Association for the Advancement of Wound Care Educates the Public 2
(Date:5/29/2015)... The science of Follicular Unit Extraction ... and more efficient methods of FUE hair transplantation have increased ... of the most cutting edge hair transplant methods being used ... technique of extracting hair from the beard to the scalp. ... to correct male pattern baldness. Beard hair has a ...
(Date:5/29/2015)... May 29, 2015 On May 21, 2015, ... be When You Get Botox ?” reported on the ... Google. Elle partnered with Google to determine these results and ... searched question in California, for example, is how to ... common search query is what's the appropriate age to start ...
(Date:5/29/2015)... To compile the list, the Becker's Hospital ... several awards for clinical and general excellence. The team ... to them in terms of overall excellence, and those ... 50 Great Health Systems to Know 2015 list includes ... Fla.) , Advocate Health Care (Downers Grove, Ill.) , ...
(Date:5/29/2015)... California (PRWEB) May 29, 2015 A group ... and have joined the national effort to teach this “new ... in the U.S. have been “sickened” by the recent implementation ... love it or hate it, Common Core is now a ... of Columbia. Parents are now seeking ways to improve ...
(Date:5/29/2015)... 2015 Inspire Nexus, a new social ... to the question many life coaches have asked, "How ... and hours necessary to become a credentialed Coach?" , ... but not for long. Inspire Nexus, a social network ... directly. Coaches who have experience coaching a certain number ...
Breaking Medicine News(10 mins):Health News:Beard to Scalp Hair Transplant: Newest Advance in Hair Transplant Technology 2Health News:Botox, Wrinkles and Double Chins: The Most-Asked Beauty Problems According to Google 2Health News:Becker's Hospital Review Names 50 Great Health Systems to Know 2Health News:Becker's Hospital Review Names 50 Great Health Systems to Know 3Health News:Doctors Discover a Cure for the Common Core 2
... The Center for Professional Innovation & Education (CfPIE) announced today ... existing list of highly-successful biotech and pharmaceutical training courses. ... developed to provide life sciences personnel with the kind of ... , ...
... , ... Denver, CO (PRWEB) July 8, 2008 --Innovative Routines ... FL, has just recorded its 30th year in the software industry ... in particular. IRI's flagship CoSort product is used worldwide in legacy ...
... to recruit large percentage of African American ... ... double,a person,s weight loss according to a study from Kaiser Permanente,s Center,for ... loss maintenance trials ever conducted, will be published in,the August issue of ...
... 7 Accuray,Incorporated (Nasdaq: ARAY ), a global ... will report results for its fourth quarter and,fiscal year ... 2008 after,the market closes., A conference call to ... p.m. EDT) and will be hosted by Euan S. ...
... Calif., July 7 Nationwide,Health Properties, Inc. (NYSE: ... second quarter earnings on Wednesday, August 6, 2008 after ... The Company will host a,conference call on Thursday, August ... time) in order to present the Company,s financial,performance and ...
... molecular "smart bombs" to target metastasis with anti-cancer drugs ... toxic chemotherapy, with less collateral damage to surrounding tissue, ... University of California, San Diego. By designing a ... led by Moores UCSD Cancer Center Director of Translational ...
Cached Medicine News:Health News:The Center for Professional Innovation and Education (CfPIE) Announces a New Global Regulatory Certification Track 2Health News:The Center for Professional Innovation and Education (CfPIE) Announces a New Global Regulatory Certification Track 3Health News:IRI, The CoSort Company, Marks 30 Years 2Health News:IRI, The CoSort Company, Marks 30 Years 3Health News:Kaiser Permanente Study Finds Keeping a Food Diary Doubles Diet Weight Loss 2Health News:Kaiser Permanente Study Finds Keeping a Food Diary Doubles Diet Weight Loss 3Health News:Kaiser Permanente Study Finds Keeping a Food Diary Doubles Diet Weight Loss 4Health News:Accuray Incorporated to Report Fourth Quarter and Fiscal Year 2008 Financial Results 2Health News:NHP Announces Second Quarter Earnings Release Date and Conference Call/Webcast 2Health News:NHP Announces Second Quarter Earnings Release Date and Conference Call/Webcast 3Health News:'Smart bomb' nanoparticle strategy impacts metastasis 2
Inquire...
Quick Release Holder for the 8000 Series Sliding Microtome. A simple to use hlder for wax cassettes. Accepts standard size wax cassettes (26 x 31 x 5mm). Can be specified instead of standard vice ...
Tilt Adapter for the 8000 Sliding Microtome to allow for orientation of the specimen....
... new SureCut M3500 Radial Microtome has a look ... and a range of functions and capabilities that ... Based on years of experience and knowledge but ... the SureCut M3500 Microtome will be the answer ...
Medicine Products: